Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vibrio cholerae O1 whole-cell antigens are the primary immunogenic components utilized in the formulation of oral cholera vaccines (OCVs) to provide protection against the bacterium responsible for epidemic cholera (World Health Organization, 2023). These antigens typically comprise heat- or formalin-inactivated whole cells of the V. cholerae O1 serogroup, encompassing both the Ogawa and Inaba serotypes and the El Tor and Classical biotypes (CDC, 2022). The most critical component is the O1-specific lipopolysaccharide (LPS), which serves as the major target for the host's immune system to generate protective vibriocidal antibodies and mucosal secretory IgA (Levine et al., 2017, PubMed). By stimulating a robust immune response against these surface structures, the vaccines prevent the bacteria from colonizing the intestinal mucosa, thereby inhibiting the progression of the disease and the subsequent release of cholera toxin (Sack et al., 2004, The Lancet). These antigens are essential for both reactive outbreak control and long-term preventative strategies in cholera-endemic areas. In addition to LPS, other surface proteins and, in some formulations, the cholera toxin B-subunit (CTB) contribute to the overall efficacy of the immune response (Wierzba et al., 2015). The use of whole-cell antigens ensures a broad spectrum of epitopes are presented to the immune system, mimicking a natural infection without the risk of disease. Clinical monitoring of the response to these antigens is primarily conducted through the measurement of serum vibriocidal antibody titers, which correlate with protection levels in vaccinated individuals.
Induction of mucosal and systemic immunity, primarily through the production of vibriocidal antibodies and secretory IgA (sIgA) targeting the O1 lipopolysaccharide, which prevents bacterial attachment and colonization in the small intestine.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vibrio cholerae O1 whole-cell antigens (V. cholerae O1 antigens).